“我们相信BluejayTherapeutics公司将为开发慢性乙肝病毒感染的功能性治愈疗法做出重大贡献,期待很快看到临床数据。”领投本轮融资的Arkin Bio Ventures的投资经理Alon Lazarus博士表示。 参考资料: [1] BluejayTherapeuticsraises $41 million in Series B round to drive clinical trials in chronic hepatitis. Retrieved A...
Bluejay Therapeutics focuses on the healthcare sector, specifically in the field of infectious diseases and liver conditions. The company's main offerings include the discovery and development of medicines and cures for viral and liver diseases, with a particular emphasis on chronic hepatitis B (CHB...